PD－L1抑制剂-话题@MedSci

#PD－L1抑制剂#

32篇内容 | 1861人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1656465, encodeId=ef661656465d3, content=<a href='/topic/show?id=14001392e65' target=_blank style='color:#2F92EE;'>#PD－L1抑制剂#</a>, objectTitle=当PD-1 / PD-L1抑制剂耐药时，MRx0518联合KEYTRUDA是一种潜在治疗手段, objectType=article, longId=182558, objectId=c766182558a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c766182558a7, replyNumber=0, likeNumber=109, createdTime=2020-04-24, rootId=0, userName=LSJ119, userId=d5eb24855327, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c766182558a7, moduleTitle=当PD-1 / PD-L1抑制剂耐药时，MRx0518联合KEYTRUDA是一种潜在治疗手段, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c766182558a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1656463, encodeId=39551656463ce, content=<a href='/topic/show?id=14001392e65' target=_blank style='color:#2F92EE;'>#PD－L1抑制剂#</a>, objectTitle=Maxinovel的口服PD-L1抑制剂被证明与PD-L1单抗Durvalumab有相似活性, objectType=article, longId=164834, objectId=5f4516483459, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f4516483459, replyNumber=0, likeNumber=62, createdTime=2020-01-04, rootId=0, userName=LSJ119, userId=d5eb24855327, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f4516483459, moduleTitle=Maxinovel的口服PD-L1抑制剂被证明与PD-L1单抗Durvalumab有相似活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5f4516483459)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1656464, encodeId=653316564640d, content=<a href='/topic/show?id=14001392e65' target=_blank style='color:#2F92EE;'>#PD－L1抑制剂#</a>, objectTitle=国内PD-1/PD-L1抑制剂亟需冷静, objectType=article, longId=179967, objectId=0ce11e9967da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ce11e9967da, replyNumber=0, likeNumber=64, createdTime=2019-09-25, rootId=0, userName=LSJ119, userId=d5eb24855327, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ce11e9967da, moduleTitle=国内PD-1/PD-L1抑制剂亟需冷静, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ce11e9967da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1656462, encodeId=d3751656462f8, content=<a href='/topic/show?id=14001392e65' target=_blank style='color:#2F92EE;'>#PD－L1抑制剂#</a>, objectTitle=宝刀尚未老，新剑已开锋——PD-1/PD-L1抑制剂的现状和新机遇, objectType=article, longId=163480, objectId=b6cb163480f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6cb163480f2, replyNumber=0, likeNumber=71, createdTime=2020-03-15, rootId=0, userName=LSJ119, userId=d5eb24855327, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6cb163480f2, moduleTitle=宝刀尚未老，新剑已开锋——PD-1/PD-L1抑制剂的现状和新机遇, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6cb163480f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1656461, encodeId=6a7a1656461fe, content=<a href='/topic/show?id=14001392e65' target=_blank style='color:#2F92EE;'>#PD－L1抑制剂#</a>, objectTitle=JCO：PD-1/PD-L1抑制剂初始治疗NSCLC 糖皮质激素让抗癌神药部分失效, objectType=article, longId=154370, objectId=61761543e050, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61761543e050, replyNumber=0, likeNumber=78, createdTime=2019-06-12, rootId=0, userName=LSJ119, userId=d5eb24855327, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61761543e050, moduleTitle=JCO：PD-1/PD-L1抑制剂初始治疗NSCLC 糖皮质激素让抗癌神药部分失效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=61761543e050)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1656459, encodeId=8a32165645988, content=<a href='/topic/show?id=14001392e65' target=_blank style='color:#2F92EE;'>#PD－L1抑制剂#</a>, objectTitle=BMJ：PD-L1在癌症中的表达状态与PD-1或PD-L1抑制剂的疗效, objectType=article, longId=148592, objectId=7d6414859221, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d6414859221, replyNumber=0, likeNumber=62, createdTime=2019-04-18, rootId=0, userName=LSJ119, userId=d5eb24855327, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d6414859221, moduleTitle=BMJ：PD-L1在癌症中的表达状态与PD-1或PD-L1抑制剂的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7d6414859221)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1656460, encodeId=64421656460b2, content=<a href='/topic/show?id=14001392e65' target=_blank style='color:#2F92EE;'>#PD－L1抑制剂#</a>, objectTitle=马军教授：PD-1/PD-L1抑制剂在淋巴瘤领域中前景无限, objectType=article, longId=149879, objectId=d9c41498e99b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9c41498e99b, replyNumber=0, likeNumber=112, createdTime=2019-05-11, rootId=0, userName=LSJ119, userId=d5eb24855327, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9c41498e99b, moduleTitle=马军教授：PD-1/PD-L1抑制剂在淋巴瘤领域中前景无限, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d9c41498e99b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1656458, encodeId=7b131656458d2, content=<a href='/topic/show?id=14001392e65' target=_blank style='color:#2F92EE;'>#PD－L1抑制剂#</a>, objectTitle=Lancet Oncol：放疗与PD-L1抑制剂：携手共抗肺癌(KEYNOTE-001), objectType=article, longId=100336, objectId=ff47100336ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ff47100336ed, replyNumber=0, likeNumber=71, createdTime=2017-11-13, rootId=0, userName=LSJ119, userId=d5eb24855327, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ff47100336ed, moduleTitle=Lancet Oncol：放疗与PD-L1抑制剂：携手共抗肺癌(KEYNOTE-001), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ff47100336ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1656457, encodeId=9e18165645eac, content=<a href='/topic/show?id=14001392e65' target=_blank style='color:#2F92EE;'>#PD－L1抑制剂#</a>, objectTitle=Chest：非小细胞肺癌患者采用PD-1和PD-L1抑制剂肺炎发生率有何差异？, objectType=article, longId=98586, objectId=24189858651, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=24189858651, replyNumber=0, likeNumber=79, createdTime=2017-08-12, rootId=0, userName=LSJ119, userId=d5eb24855327, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=24189858651, moduleTitle=Chest：非小细胞肺癌患者采用PD-1和PD-L1抑制剂肺炎发生率有何差异？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=24189858651)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1656456, encodeId=b54416564565e, content=<a href='/topic/show?id=14001392e65' target=_blank style='color:#2F92EE;'>#PD－L1抑制剂#</a>, objectTitle=PD-1/PD-L1抑制剂市场再添一员！阿斯利康PD-L1抑制剂Imfinzi获FDA加速批准, objectType=article, longId=101079, objectId=78e61010e913, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=78e61010e913, replyNumber=0, likeNumber=59, createdTime=2017-09-24, rootId=0, userName=LSJ119, userId=d5eb24855327, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=78e61010e913, moduleTitle=PD-1/PD-L1抑制剂市场再添一员！阿斯利康PD-L1抑制剂Imfinzi获FDA加速批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=78e61010e913)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1656455, encodeId=57fa165645526, content=<a href='/topic/show?id=14001392e65' target=_blank style='color:#2F92EE;'>#PD－L1抑制剂#</a>, objectTitle=重磅！第一个PD－L1抑制剂获得转移期NSCLC适应症, objectType=article, longId=80506, objectId=016d805060a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=016d805060a, replyNumber=0, likeNumber=62, createdTime=2017-09-02, rootId=0, userName=LSJ119, userId=d5eb24855327, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=016d805060a, moduleTitle=重磅！第一个PD－L1抑制剂获得转移期NSCLC适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=016d805060a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1656454, encodeId=cc92165645416, content=<a href='/topic/show?id=14001392e65' target=_blank style='color:#2F92EE;'>#PD－L1抑制剂#</a>, objectTitle=阿斯利康将携手Peregrine展开PD-L1抑制剂durvalumab联合用药研究, objectType=article, longId=70377, objectId=eb3fe037703, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb3fe037703, replyNumber=0, likeNumber=117, createdTime=2016-08-17, rootId=0, userName=LSJ119, userId=d5eb24855327, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb3fe037703, moduleTitle=阿斯利康将携手Peregrine展开PD-L1抑制剂durvalumab联合用药研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb3fe037703)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1656453, encodeId=8d3e165645319, content=<a href='/topic/show?id=14001392e65' target=_blank style='color:#2F92EE;'>#PD－L1抑制剂#</a>, objectTitle=FDA批准PD-L1抑制剂——罗氏Tecentriq (atezolizumab)治疗尿路上皮癌, objectType=article, longId=68717, objectId=7e3c68e17a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e3c68e17a3, replyNumber=0, likeNumber=50, createdTime=2016-09-06, rootId=0, userName=LSJ119, userId=d5eb24855327, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e3c68e17a3, moduleTitle=FDA批准PD-L1抑制剂——罗氏Tecentriq (atezolizumab)治疗尿路上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e3c68e17a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PD－L1抑制剂

2020-05-29

LSJ119 (审核中...)

前往app查看评论内容

#PD－L1抑制剂#

当PD-1 / PD-L1抑制剂耐药时，MRx0518联合KEYTRUDA是一种潜在治疗手段

2020-04-24

LSJ119 (审核中...)

前往app查看评论内容

#PD－L1抑制剂#

Maxinovel的口服PD-L1抑制剂被证明与PD-L1单抗Durvalumab有相似活性

2020-01-04

LSJ119 (审核中...)

前往app查看评论内容

#PD－L1抑制剂#

国内PD-1/PD-L1抑制剂亟需冷静

2019-09-25

LSJ119 (审核中...)

前往app查看评论内容

#PD－L1抑制剂#

宝刀尚未老，新剑已开锋——PD-1/PD-L1抑制剂的现状和新机遇

2020-03-15

LSJ119 (审核中...)

前往app查看评论内容

#PD－L1抑制剂#

JCO：PD-1/PD-L1抑制剂初始治疗NSCLC 糖皮质激素让抗癌神药部分失效

2019-06-12

LSJ119 (审核中...)

前往app查看评论内容

#PD－L1抑制剂#

BMJ：PD-L1在癌症中的表达状态与PD-1或PD-L1抑制剂的疗效

2019-04-18

LSJ119 (审核中...)

前往app查看评论内容

#PD－L1抑制剂#

马军教授：PD-1/PD-L1抑制剂在淋巴瘤领域中前景无限

2019-05-11

LSJ119 (审核中...)

前往app查看评论内容

#PD－L1抑制剂#

Lancet Oncol：放疗与PD-L1抑制剂：携手共抗肺癌(KEYNOTE-001)

2017-11-13

LSJ119 (审核中...)

前往app查看评论内容

#PD－L1抑制剂#

Chest：非小细胞肺癌患者采用PD-1和PD-L1抑制剂肺炎发生率有何差异？

2017-08-12

LSJ119 (审核中...)

前往app查看评论内容

#PD－L1抑制剂#

PD-1/PD-L1抑制剂市场再添一员！阿斯利康PD-L1抑制剂Imfinzi获FDA加速批准

2017-09-24

LSJ119 (审核中...)

前往app查看评论内容

#PD－L1抑制剂#

重磅！第一个PD－L1抑制剂获得转移期NSCLC适应症

2017-09-02

LSJ119 (审核中...)

前往app查看评论内容

#PD－L1抑制剂#

阿斯利康将携手Peregrine展开PD-L1抑制剂durvalumab联合用药研究

2016-08-17

LSJ119 (审核中...)

前往app查看评论内容

#PD－L1抑制剂#

FDA批准PD-L1抑制剂——罗氏Tecentriq (atezolizumab)治疗尿路上皮癌

2016-09-06

科室
- - 订阅+
  - 更多科室
工具
服务